MARKET

LRMR

LRMR

Larimar Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.690
+0.085
+3.26%
After Hours: 2.690 0 0.00% 16:00 05/19 EDT
OPEN
2.690
PREV CLOSE
2.605
HIGH
2.710
LOW
2.640
VOLUME
15.59K
TURNOVER
0
52 WEEK HIGH
15.49
52 WEEK LOW
2.400
MARKET CAP
47.64M
P/E (TTM)
-0.9086
1D
5D
1M
3M
1Y
5Y
Larimar Therapeutics Announces Upcoming Poster Presentations at the 4th Pan American Parkinson’s Disease and Movement Disorders Congress
BALA CYNWYD, Pa., May 19, 2022 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that data from the Company’s Phase ...
GlobeNewswire · 9h ago
Stocks That Hit 52-Week Lows On Monday
  On Monday, 198 companies reached new 52-week lows.
Benzinga · 3d ago
Larimar Therapeutics GAAP EPS of -$0.49
Larimar Therapeutics press release (NASDAQ:LRMR): Q1 GAAP EPS of -$0.49. As of March 31, 2022, the Company had cash and cash equivalents totaling $62.6 million which provides projected cash runway
Seekingalpha · 05/12 12:22
Despite recent gains, Larimar Therapeutics, Inc. (NASDAQ:LRMR) insiders are still down US$273k after purchasing last year
Some of the losses seen by insiders who purchased US$496k worth of Larimar Therapeutics, Inc. ( NASDAQ:LRMR ) shares...
Simply Wall St. · 04/29 10:27
Down 21.2% in 4 Weeks, Here's Why You Should You Buy the Dip in Larimar (LRMR)
Larimar (LRMR) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend re...
Zacks · 04/13 14:40
Larimar Therapeutics GAAP EPS of -$0.50 beats by $0.22
Larimar Therapeutics press release (NASDAQ:LRMR): Q4 GAAP EPS of -$0.50 beats by $0.22. As of December 31, 2021, cash and cash equivalents totaling $70.1M.
Seekingalpha · 03/25 11:26
BRIEF-Larimar Therapeutics Reports Fourth Quarter And Full Year 2021 Operating And Financial Results
reuters.com · 03/25 11:07
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Benzinga · 02/17 13:11
More
No Data
Learn about the latest financial forecast of LRMR. Analyze the recent business situations of Larimar Therapeutics Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Hold

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

0.00%Strong Buy
33.33%Buy
66.67%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average LRMR stock price target is 5.50 with a high estimate of 8.00 and a low estimate of 3.000.
High8.00
Average5.50
Low3.000
Current 2.690
EPS
Actual
Estimate
-0.74-0.55-0.37-0.18
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 83
Institutional Holdings: 14.86M
% Owned: 83.88%
Shares Outstanding: 17.71M
TypeInstitutionsShares
Increased
12
494.98K
New
5
381.42K
Decreased
12
318.95K
Sold Out
9
415.58K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.00%
Pharmaceuticals & Medical Research
+0.51%
Key Executives
Non-Executive Chairman/Independent Director
Joseph Truitt
President/Chief Executive Officer/Director
Carole Ben-Maimon
Chief Financial Officer/Secretary
Michael Celano
Independent Director
Peter Barrett
Independent Director
Thomas Hamilton
Independent Director
Jonathan Leff
Independent Director
Frank Thomas
No Data
No Data
About LRMR
Larimar Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for patients suffering from complex rare diseases using its cell penetrating peptide technology platform. The Company's protein replacement therapy platform is intended to deliver missing proteins inside the machinery of cells to treat devastating rare diseases that is ineffective or no treatments available. Its cell penetrating peptide ( CPP) technology platform, which enables a therapeutic molecule to cross a cell membrane in order to reach intracellular targets that has the potential to enable the treatment of other rare and orphan diseases. The Company's lead product candidate, CTI-1601, is a recombinant fusion protein intended to deliver human frataxin ( FXN), an essential protein to the mitochondria of patients with Friedreich’s ataxia. CTI-1601 is in Phase I clinical program.

Webull offers kinds of Larimar Therapeutics Inc stock information, including NASDAQ:LRMR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LRMR stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading LRMR stock methods without spending real money on the virtual paper trading platform.